These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 22303947)

  • 41. Kinetics and molecular docking studies of kaempferol and its prenylated derivatives as aldose reductase inhibitors.
    Jung HA; Moon HE; Oh SH; Kim BW; Sohn HS; Choi JS
    Chem Biol Interact; 2012 May; 197(2-3):110-8. PubMed ID: 22543015
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Artificial neural networks-based approach to design ARIs using QSAR for diabetes mellitus.
    Patra JC; Singh O
    J Comput Chem; 2009 Nov; 30(15):2494-508. PubMed ID: 19373836
    [TBL] [Abstract][Full Text] [Related]  

  • 43. In vitro and in vivo inhibition of aldose reductase and advanced glycation end products by phloretin, epigallocatechin 3-gallate and [6]-gingerol.
    Sampath C; Sang S; Ahmedna M
    Biomed Pharmacother; 2016 Dec; 84():502-513. PubMed ID: 27685794
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Aldose Reductase as a Drug Target for Treatment of Diabetic Nephropathy: Promises and Challenges.
    ElGamal H; Munusamy S
    Protein Pept Lett; 2017; 24(1):71-77. PubMed ID: 27894247
    [TBL] [Abstract][Full Text] [Related]  

  • 45. All in the family.
    Harrison DH
    Nat Struct Biol; 1995 Sep; 2(9):719-20. PubMed ID: 7552737
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Synthesis and biological evaluation of some new pyrazoline substituted benzenesulfonylurea/thiourea derivatives as anti-hyperglycaemic agents and aldose reductase inhibitors.
    Ovais S; Pushpalatha H; Reddy GB; Rathore P; Bashir R; Yaseen S; Dheyaa A; Yaseen R; Tanwar O; Akthar M; Samim M; Javed K
    Eur J Med Chem; 2014 Jun; 80():209-17. PubMed ID: 24780598
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Identification of an aldose reductase inhibitor site by affinity labeling.
    Kador PF; Lee YS; Rodriguez L; Sato S; Bartoszko-Malik A; Abdel-Ghany YS; Miller DD
    Bioorg Med Chem; 1995 Oct; 3(10):1313-24. PubMed ID: 8564397
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The efficacy of aldose reductase inhibitors in the management of diabetic complications. Comparison with intensive insulin treatment and pancreatic transplantation.
    van Gerven JM; Tjon-A-Tsien AM
    Drugs Aging; 1995 Jan; 6(1):9-28. PubMed ID: 7696781
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The effect of aldose reductase inhibitors on glomerular prostaglandin production and urinary albumin excretion in experimental diabetes mellitus.
    Chang WP; Dimitriadis E; Allen T; Dunlop ME; Cooper M; Larkins RG
    Diabetologia; 1991 Apr; 34(4):225-31. PubMed ID: 1906023
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Current advances in the treatment of diabetes mellitus].
    Ohta M
    Nihon Ika Daigaku Zasshi; 1999 Jun; 66(3):195-8. PubMed ID: 10401238
    [No Abstract]   [Full Text] [Related]  

  • 51. Novel spirosuccinimides with incorporated isoindolone and benzisothiazole 1,1-dioxide moieties as aldose reductase inhibitors and antihyperglycemic agents.
    Wrobel J; Dietrich A; Woolson SA; Millen J; McCaleb M; Harrison MC; Hohman TC; Sredy J; Sullivan D
    J Med Chem; 1992 Nov; 35(24):4613-27. PubMed ID: 1469692
    [TBL] [Abstract][Full Text] [Related]  

  • 52. In silico Designing of Novel Inhibitors for Triple Inhibition of Aldose Reductase, Aldose Reductase Like Protein 1, and Aldehyde Reductase.
    Devi A
    Curr Comput Aided Drug Des; 2020; 16(6):707-717. PubMed ID: 31749429
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Exploiting oxadiazole-sulfonamide hybrids as new structural leads to combat diabetic complications via aldose reductase inhibition.
    Javid N; Munir R; Chaudhry F; Imran A; Zaib S; Muzaffar A; Iqbal J
    Bioorg Chem; 2020 Jun; 99():103852. PubMed ID: 32325339
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Pursuing aldose reductase inhibitors through in situ cross-docking and similarity-based virtual screening.
    Cosconati S; Marinelli L; La Motta C; Sartini S; Da Settimo F; Olson AJ; Novellino E
    J Med Chem; 2009 Sep; 52(18):5578-81. PubMed ID: 19719141
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Aldose reductase inhibitors in the treatment of diabetic peripheral neuropathy: a review.
    Schemmel KE; Padiyara RS; D'Souza JJ
    J Diabetes Complications; 2010; 24(5):354-60. PubMed ID: 19748287
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Alkaloids as aldose reductase inhibitors, with special reference to berberine.
    Gupta S; Singh N; Jaggi AS
    J Altern Complement Med; 2014 Mar; 20(3):195-205. PubMed ID: 24236461
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Synthesis, characterization, hypoglycemic and aldose reductase inhibition activity of arylsulfonylspiro[fluorene-9,5'-imidazolidine]-2',4'-diones.
    Iqbal Z; Hameed S; Ali S; Tehseen Y; Shahid M; Iqbal J
    Eur J Med Chem; 2015 Jun; 98():127-38. PubMed ID: 26005026
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Discovery of new selective human aldose reductase inhibitors through virtual screening multiple binding pocket conformations.
    Wang L; Gu Q; Zheng X; Ye J; Liu Z; Li J; Hu X; Hagler A; Xu J
    J Chem Inf Model; 2013 Sep; 53(9):2409-22. PubMed ID: 23901876
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Pterin-7-carboxamides as a new class of aldose reductase inhibitors.
    Saito R; Suzuki S; Sasaki K
    Bioorg Med Chem Lett; 2016 Oct; 26(20):4870-4874. PubMed ID: 27666634
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Aldose reductase inhibitors.
    Kirchain WR; Rendell MS
    Pharmacotherapy; 1990; 10(5):326-36. PubMed ID: 2122421
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.